PHAT
BULLISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Trades at a premium to book value but a deep discount to forward earnings relative to peers.
- Forward P/E (8.17) is very low for the sector
- Negative Price/Book ratio
- No Graham Number available due to lack of earnings
Growth rates are significantly higher than the average for the market cap peer group.
- 94% YoY Revenue growth
- Strong analyst target price
- Dependence on commercialization success
Recent momentum is strong, but long-term recovery is still in progress.
- 1-year return of +198.5%
- 5-year return of -65.2%
Stable by Piotroski standards, but fundamentally fragile due to negative equity.
- Current Ratio 1.73
- Piotroski F-Score 4/9 (Stable)
- Negative ROA (-31.37%)
- Negative equity
Typical for growth-stage biotech companies.
- No dividend paid
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for PHAT and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
PHAT
Phathom Pharmaceuticals, Inc.
Primary
|
-65.2% | +21.0% | +198.5% | -5.3% | +16.2% | -0.2% |
|
CLOV
Clover Health Investments, Corp.
Peer
|
-78.5% | +126.7% | -40.8% | -29.6% | -5.0% | +8.0% |
|
ASTH
Astrana Health, Inc.
Peer
|
-19.7% | -41.8% | -41.4% | -36.4% | -7.6% | +2.4% |
|
PCRX
Pacira BioSciences, Inc.
Peer
|
-62.4% | -44.9% | -2.5% | +4.8% | +8.8% | +0.2% |
|
EVO
Evotec SE
Peer
|
-85.8% | -75.5% | -11.5% | -32.4% | -11.2% | +5.9% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
PHAT
Phathom Pharmaceuticals, Inc.
|
BULLISH | $1.0B | - | -% | -126.3% | $12.61 | |
|
CLOV
Clover Health Investments, Corp.
|
BEARISH | $996.87M | - | -26.3% | -4.4% | $1.9 | Compare |
|
ASTH
Astrana Health, Inc.
|
BEARISH | $1.02B | 107.0 | 1.8% | 0.3% | $20.33 | Compare |
|
PCRX
Pacira BioSciences, Inc.
|
BEARISH | $1.03B | 149.12 | 1.0% | 1.0% | $23.86 | Compare |
|
EVO
Evotec SE
|
BEARISH | $963.68M | - | -18.0% | -21.0% | $2.69 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-10 | PARIKH ASIT | Director | Gift | 40,000 | - |
| 2026-02-27 | BREEDLOVE ROBERT CHARLES | Officer | Stock Award | 15,790 | - |
| 2026-02-10 | BASTA STEVEN L | Chief Executive Officer | Stock Award | 12,362 | - |
| 2026-02-10 | COOK ANNE MARIE | Officer | Stock Award | 3,461 | - |
| 2026-01-23 | PARIKH ASIT | Director | Gift | 80,500 | - |
| 2026-01-13 | PARIKH ASIT | Director | Option Exercise | 8,750 | $90,125 |
| 2026-01-02 | BASTA STEVEN L | Officer and Director | Stock Award | 251,034 | - |
| 2026-01-02 | COOK ANNE MARIE | Officer | Stock Award | 75,345 | - |
| 2026-01-02 | NARULA SANJEEV | Chief Financial Officer | Stock Award | 82,715 | - |
| 2025-12-19 | PARIKH ASIT | Director | Option Exercise | 8,750 | $90,125 |
| 2025-12-17 | BASTA STEVEN L | Chief Executive Officer | Stock Award | 62,038 | - |
| 2025-12-17 | COOK ANNE MARIE | Officer | Stock Award | 17,370 | - |
| 2025-11-28 | BASTA STEVEN L | Chief Executive Officer | Stock Award | 90,000 | - |
| 2025-11-03 | BREEDLOVE ROBERT CHARLES | Officer | Sale | 524 | $7,079 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
PHAT's 10-Q filing dated October 30, 2025, indicates significant financial risks, specifically noting defaults upon senior securities. The company also reports the unregistered sale of equity securities, suggesting a reliance on equity financing to manage its capital structure and obligations.
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning PHAT from our newsroom.